查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1388042

全球癌症生物标记市场：份额、规模、趋势、产业分析 - 按类型、生物分子、应用、细分市场预测，2023-2032 年

Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2032 年，全球癌症生物标记市场规模将达到 533.6 亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

针对新型癌症生物标记的药物开发不断加大努力和投资，在推动癌症生物标记市场的成长潜力方面发挥关键作用。 这些生物标记作为癌细胞特定特征的指标，有助于开发更有针对性和更有效的治疗方法。 透过关注这些独特的生物标记物，製药公司可以开发针对特定癌症亚型的药物，从而改善治疗结果并减少副作用。

此外，技术先进的伴随诊断试剂盒的推出将补充标靶治疗的开发。 这些诊断试剂盒有助于识别患者体内是否存在特定的生物标记物，使医疗保健专业人员能够根据患者的个人资料製定个人化的治疗计划。 这些诊断试剂盒指导下的个人化医疗可确保患者获得最佳治疗，从而产生更好的治疗反应并改善患者的整体治疗结果。

政府支持的旨在推动新型癌症诊断技术的措施也推动了成长。 例如，美国国家癌症研究所 (NCI) 向超过八个专门致力于开发癌症生物标记的研究领域分配资金。 英国癌症研究中心、肺癌研究基金会和美国国立卫生研究院等其他组织也透过资助以生物标记为中心的研究计画发挥重要作用。 这些措施正在促进该领域的创新和研究，并加速新癌症诊断技术的进步。

大量饮酒、吸烟、饮食不健康以及久坐生活方式的人比生活方式健康的人更容易患癌症。研究发现，患癌症的可能性高出 80% 此外，某些感染，如人类乳突病毒 (HPV)、EB 病毒、B型肝炎病毒和幽门螺旋桿菌，也正在研究它们与癌症发展的可能关联。

癌症生物标记市场报告亮点

由于乳癌病例数量不断增加、生物标记的广泛研究以及主要产品的推出，乳癌获得了最大的市场份额

由于患有遗传疾病和相关疾病情况的患者数量不断增加，遗传生物标记正在迅速增长

由于个人化治疗方案的最新进展，个人化医疗可能会快速成长。

由于消费者意识、熟练外科医生的存在以及更好的医疗基础设施，北美在 2022 年占据了最大的市场份额。

主要参与者包括Abbott Laboratories、Thermo Fisher Scientific、Affymetrix、Illumina、Agilent Technologies、Merck、Hologic、Roche、QIAGEN、Sino Biological、Becton等。

目录

第 1 章简介

第 2 章执行摘要

第 3 章研究方法

第 4 章全球癌症生物标记市场洞察

  • 癌症生物标记市场 - 生物分子概况
  • 癌症生物标记市场动态
    • 促进因素和机会
    • 抑制因素和挑战
  • PESTEL 分析
  • 癌症生物标记市场的生物分子趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第 5 章全球癌症生物标记市场（按类型）

  • 主要发现
  • 简介
  • 乳癌
  • 摄护腺癌
  • 大肠癌
  • 子宫颈癌
  • 肝癌
  • 肺癌
  • 其他

第 6 章全球癌症生物标记市场（按应用）

  • 主要发现
  • 简介
  • 药物发现/开发
  • 诊断
  • 个人化医疗
  • 其他

第 7 章全球癌症生物标记市场（按生物分子）

  • 主要发现
  • 简介
  • 遗传生物标记
  • 表观遗传生物标记
  • 代谢生物标记
  • 蛋白质体学生物标誌物
  • 其他

第 8 章全球癌症生物标记市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年癌症生物标记市场评估（按地区）
  • 癌症生物标记市场 - 北美
    • 北美：癌症生物标记市场（按类型），2019-2032 年
    • 北美：癌症生物标记市场，依生物分子划分，2019-2032 年
    • 北美：癌症生物标记市场，按应用划分，2019-2032 年
    • 癌症生物标记市场 - 美国
    • 癌症生物标记市场 - 加拿大
  • 癌症生物标记市场 - 欧洲
    • 欧洲：癌症生物标记市场（按类型），2019-2032 年
    • 欧洲：癌症生物标记市场，依生物分子分类，2019-2032 年
    • 欧洲：癌症生物标记市场，按应用划分，2019-2032 年
    • 癌症生物标记市场 - 英国
    • 癌症生物标记市场 - 法国
    • 癌症生物标记市场 - 德国
    • 癌症生物标记市场 - 义大利
    • 癌症生物标记市场 - 西班牙
    • 癌症生物标记市场 - 荷兰
    • 癌症生物标记市场 - 俄罗斯
  • 癌症生物标记市场 - 亚太地区
    • 亚太地区：癌症生物标记市场（按类型），2019-2032 年
    • 亚太地区：癌症生物标记市场，依生物分子划分，2019-2032 年
    • 亚太地区：癌症生物标记市场，按应用划分，2019-2032 年
    • 癌症生物标记市场—中国
    • 癌症生物标记市场—印度
    • 癌症生物标记市场 - 马来西亚
    • 癌症生物标记市场 - 日本
    • 癌症生物标记市场 - 印尼
    • 癌症生物标记市场－韩国
  • 癌症生物标记市场 - 中东和非洲
    • 中东和非洲：癌症生物标记市场（按类型），2019-2032 年
    • 中东和非洲：癌症生物标记市场，按生物分子分类，2019-2032 年
    • 中东和非洲：癌症生物标记市场，按应用划分，2019-2032 年
    • 癌症生物标记市场 - 沙乌地阿拉伯
    • 癌症生物标记市场－阿拉伯联合大公国
    • 癌症生物标记市场 - 以色列
    • 癌症生物标记市场 - 南非
  • 癌症生物标记市场 - 拉丁美洲
    • 拉丁美洲：癌症生物标记市场（按类型），2019-2032 年
    • 拉丁美洲：癌症生物标记市场，按生物分子分类，2019-2032 年
    • 拉丁美洲：癌症生物标记市场，按应用划分，2019-2032 年
    • 癌症生物标记市场—墨西哥
    • 癌症生物标记市场 - 巴西
    • 癌症生物标记市场－阿根廷

第 9 章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第 10 章公司简介

  • Abbott Laboratories
  • Agilent Technologies
  • Affymetrix
  • Becton
  • Hologic
  • Illumina
  • Merck
  • QIAGEN
  • Roche
  • Sino Biological
  • Thermo Fisher Scientific
Product Code: PM3738

The global cancer biomarkers market size is expected to reach USD 53.36 billion by 2032, according to a new study by Polaris market research. The report "Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing initiatives and investments in the development of drugs that target novel cancer biomarkers play a crucial role in driving the growth potential of the cancer biomarkers market. These biomarkers serve as indicators of specific characteristics of cancer cells, enabling the development of more targeted and effective treatments. By focusing on these unique biomarkers, pharmaceutical companies can create drugs tailored to specific subtypes of cancer, leading to improved treatment outcomes and reduced side effects.

Moreover, the introduction of technologically advanced companion diagnostic kits complements the development of targeted therapies. These diagnostic kits help identify the presence of specific biomarkers in patients, allowing healthcare professionals to personalize treatment plans based on individual patient profiles. Personalized medicine, guided by these diagnostic kits, ensures that patients receive the most suitable treatments, leading to better treatment responses and enhanced overall patient outcomes.

Growth is also facilitated by the existence of supportive government initiatives aimed at advancing novel cancer diagnostic techniques. For instance, the National Cancer Institute (NCI) allocates funding to over 8 research areas specifically focused on the development of cancer biomarkers. Other organizations such as Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health also play a significant role by providing funding for research projects centered around biomarkers. These initiatives foster innovation and research in the field, accelerating the progress of new and improved cancer diagnostic techniques.

Individuals who engage in high alcohol consumption, use tobacco, have unhealthy dietary habits, and lead a sedentary lifestyle are found to be 80% more susceptible to developing cancer compared to those with healthier habits. Additionally, certain infections, including Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori, have also been under study for their potential association with cancer development.

Cancer Biomarkers Market Report Highlights

Breast cancer held the largest share, owing to the rising cases of breast cancer, extensive research on biomarkers, & key product launches

Genetic biomarkers will grow at the rapid pace, because of rising cases of genetic disorders, and relevant diseased scenario

Personalized medicine will grow at rapid pace, owing recent advancements in personalized treatment options

North America held the largest share of the market in 2022, owing to consumer awareness, presence of skilled surgeons with better healthcare infrastructure

Key players include Abbott Laboratories, Thermo Fisher Scientific, Affymetrix, Illumina, Agilent Technologies, Merck, Hologic, Roche, QIAGEN, Sino Biological, & Becton

Polaris market research has segmented the cancer biomarkers market report based on type, biomolecule, application, and region:

Cancer Biomarkers, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Breast cancer
  • Prostate cancer
  • Colorectal cancer
  • Cervical cancer
  • Liver cancer
  • Lung cancer
  • Others

Cancer Biomarkers, Biomolecule Outlook (Revenue - USD Billion, 2023 - 2032)

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Others

Cancer Biomarkers, Application Outlook (Revenue - USD Billion, 2023 - 2032)

  • Drug discovery and Development
  • Diagnostics
  • Personalized medicine
  • Others

Cancer Biomarkers, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Biomarkers Market Insights

  • 4.1. Cancer Biomarkers Market - Biomolecule Snapshot
  • 4.2. Cancer Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing awareness among patients and healthcare professionals about the importance of early diagnosis of malignancies.
      • 4.2.1.2. Rising demand for personalized medicine
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High capital investment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Cancer Biomarkers Market Biomolecule Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cancer Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Breast cancer
    • 5.3.1. Global Cancer Biomarkers Market, by Breast cancer, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostate cancer
    • 5.4.1. Global Cancer Biomarkers Market, by Prostate cancer, by Region, 2019-2032 (USD Billion)
  • 5.5. Colorectal cancer
    • 5.5.1. Global Cancer Biomarkers Market, by Colorectal cancer, by Region, 2019-2032 (USD Billion)
  • 5.6. Cervical cancer
    • 5.6.1. Global Cancer Biomarkers Market, by Cervical cancer, by Region, 2019-2032 (USD Billion)
  • 5.7. Liver cancer
    • 5.7.1. Global Cancer Biomarkers Market, by Liver cancer, by Region, 2019-2032 (USD Billion)
  • 5.8. Lung cancer
    • 5.8.1. Global Cancer Biomarkers Market, by Lung cancer, by Region, 2019-2032 (USD Billion)
  • 5.9. Others
    • 5.9.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Cancer Biomarkers Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Drug discovery and Development
    • 6.3.1. Global Cancer Biomarkers Market, by Drug discovery and Development, by Region, 2019-2032 (USD Billion)
  • 6.4. Diagnostics
    • 6.4.1. Global Cancer Biomarkers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
  • 6.5. Personalized medicine
    • 6.5.1. Global Cancer Biomarkers Market, by Personalized medicine, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Cancer Biomarkers Market, by Biomolecule

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • 7.3. Genetic Biomarkers
    • 7.3.1. Global Cancer Biomarkers Market, by Genetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.4. Epigenetic Biomarkers
    • 7.4.1. Global Cancer Biomarkers Market, by Epigenetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.5. Metabolic Biomarkers
    • 7.5.1. Global Cancer Biomarkers Market, by Metabolic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.6. Proteomic Biomarkers
    • 7.6.1. Global Cancer Biomarkers Market, by Proteomic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Cancer Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Cancer Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Biomarkers Market - North America
    • 8.3.1. North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Biomarkers Market - Canada
      • 8.3.5.1. Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Cancer Biomarkers Market - Europe
    • 8.4.1. Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Biomarkers Market - UK
      • 8.4.4.1. UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Biomarkers Market - France
      • 8.4.5.1. France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Biomarkers Market - Germany
      • 8.4.6.1. Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Biomarkers Market - Italy
      • 8.4.7.1. Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Biomarkers Market - Spain
      • 8.4.8.1. Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Biomarkers Market - Russia
      • 8.4.10.1. Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Cancer Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Biomarkers Market - China
      • 8.5.4.1. China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Biomarkers Market - India
      • 8.5.5.1. India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Biomarkers Market - Japan
      • 8.5.7.1. Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Cancer Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Biomarkers Market - UAE
      • 8.6.5.1. UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Biomarkers Market - Israel
      • 8.6.6.1. Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Cancer Biomarkers Market - Latin America
    • 8.7.1. Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Agilent Technologies
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Affymetrix
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Becton
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Hologic
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Illumina
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. QIAGEN
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sino Biological
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Thermo Fisher Scientific
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables

  • Table 1 Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 4 Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Cancer Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Cancer Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Biomolecule
  • Figure 11. Global Cancer Biomarkers Market, by Biomolecule, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Biomarkers Market